[{"data":1,"prerenderedAt":255},["ShallowReactive",2],{"site":3,"legal-terms":167},{"id":4,"aboutHeadline":5,"aboutIntro":6,"aboutLabel":7,"contactBody":8,"contactCta":9,"contactHeadline":12,"contactLabel":13,"designations":14,"designationsHeadline":22,"designationsLabel":23,"extension":24,"focusAreas":25,"focusHeadline":35,"focusLabel":36,"footerColumns":37,"footerCopyright":70,"footerLegalBlocks":71,"footerLegalLinks":81,"footerLogoMain":91,"footerLogoSub":92,"footerTagline":93,"heroEyebrow":94,"heroPrimaryCta":95,"heroSecondaryCta":97,"heroStats":99,"heroSubtitle":109,"heroTitle":110,"marqueeItems":111,"meta":120,"missionCallout":121,"missionHeadline":122,"missionLabel":96,"missionParagraphs":123,"navCta":126,"navLinks":128,"pipelineHeadline":137,"pipelineLabel":138,"pipelineNote":139,"pipelineStages":140,"seoDescription":162,"seoOgImage":163,"seoTitle":164,"stem":165,"__hash__":166},"site\u002Fsite\u002Findex.yml","The team behind\n*the science.*\n","ZP5 Therapeutics was co-founded by two industry veterans who previously built and sold a company together — bringing decades of combined experience in drug development, regulatory affairs, and clinical pharmacology to one of global health's most pressing problems.","About Us","Whether you're a potential partner, researcher, or investor, we'd love to share what we're working on and explore how we might work together toward better treatments for neglected diseases.",{"label":10,"href":11},"Reach Out","#contact","Want to learn more about\nZero Point Five Therapeutics?\n","Get In Touch",[15,19],{"tag":16,"title":17,"body":18},"FDA Designation","Rare Pediatric Disease Designation","Granted by the FDA in recognition of the serious and life-threatening nature of the condition in patients aged 18 and under. This designation provides eligibility for a Priority Review Voucher upon approval — a significant commercial and humanitarian milestone.",{"tag":16,"title":20,"body":21},"Orphan Drug Designation","Awarded by the FDA's Office of Orphan Products Development for our lead therapeutic candidate. This designation confers seven years of market exclusivity upon approval, tax credits for qualified clinical trials, and waiver of the Prescription Drug User Fee Act application fee.","Recognized at every level\nof *regulatory priority.*\n","Regulatory Designations","yml",[26,29,32],{"title":27,"body":28},"Neglected Tropical Diseases","Targeting parasitic and bacterial infections that afflict hundreds of millions in tropical and subtropical regions with limited access to existing treatments.",{"title":30,"body":31},"Rare & Orphan Conditions","Addressing conditions that affect small patient populations, where the commercial incentive has historically been insufficient to attract pharmaceutical investment.",{"title":33,"body":34},"Drug-Resistant Infections","Developing novel therapeutic strategies to combat the global threat of antimicrobial resistance, which disproportionately impacts resource-limited healthcare settings.","Where our *science* is directed.","Focus Areas",[38,54,62],{"heading":39,"links":40},"Company",[41,44,46,49,52],{"label":42,"href":43},"Mission","#mission",{"label":36,"href":45},"#focus",{"label":47,"href":48},"Pipeline","#approach",{"label":50,"href":51},"Designations","#designations",{"label":53,"href":11},"Contact",{"heading":55,"links":56},"Regulatory",[57,58,59],{"label":17,"href":51},{"label":20,"href":51},{"label":60,"href":61},"ClinicalTrials.gov","https:\u002F\u002Fclinicaltrials.gov",{"heading":53,"links":63},[64,67],{"label":65,"href":66},"contact@zeropointfivetherapeutics.com","mailto:contact@zeropointfivetherapeutics.com",{"label":68,"href":69},"zeropointfivetherapeutics.com","https:\u002F\u002Fzeropointfivetherapeutics.com","© 2026 Zero Point Five Therapeutics, Inc. · All Rights Reserved",[72,75,78],{"heading":73,"body":74},"Forward-Looking Statements","This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the clinical development, regulatory strategy, and potential commercialization of Zero Point Five Therapeutics, Inc.'s product candidates. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks related to clinical trial outcomes, regulatory review and approval, manufacturing, competition, and market conditions. Forward-looking statements speak only as of the date on which they are made, and Zero Point Five Therapeutics, Inc. undertakes no obligation to update or revise any forward-looking statement, except as required by law.",{"heading":76,"body":77},"Regulatory & Clinical Disclaimer","Zero Point Five Therapeutics, Inc.'s lead product candidate is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for any indication. The safety and efficacy of this investigational compound have not been established. Rare Pediatric Disease Designation and Orphan Drug Designation are granted by the FDA and are not a guarantee of regulatory approval. These designations provide certain development incentives but do not confirm that the product candidate will receive marketing approval or be commercially successful. Information on this website is intended for informational purposes only and does not constitute medical advice, a solicitation for investment, or an offer to sell securities.",{"heading":79,"body":80},"No Offer of Securities","Nothing on this website constitutes an offer to sell, or a solicitation of an offer to buy, any securities of Zero Point Five Therapeutics, Inc. Any offering of securities will be made only pursuant to a formal offering memorandum or other applicable disclosure document in compliance with applicable federal and state securities laws.",[82,85,88],{"label":83,"href":84},"Privacy Policy","\u002Flegal\u002Fprivacy",{"label":86,"href":87},"Terms of Use","\u002Flegal\u002Fterms",{"label":89,"href":90},"Cookie Policy","\u002Flegal\u002Fcookies","Zero Point Five","Therapeutics, Inc.","Developing safe and efficacious treatments\nfor neglected diseases.","Phase 3 Clinical Stage",{"label":96,"href":43},"Our Mission",{"label":98,"href":11},"Get in Touch",[100,103,106],{"number":101,"label":102},"1B+","NTD-Affected People",{"number":104,"label":105},"2B","STH Infections Worldwide",{"number":107,"label":108},"149","Countries with Endemic NTDs","Zero Point Five Therapeutics, Inc. is developing safe and efficacious therapeutic interventions for diseases that have been historically overlooked by mainstream medicine.","Treatments for *neglected* diseases.",[112,113,114,115,116,117,118,119],"Phase 3 Clinical Trial","Safe & Efficacious","Neglected Diseases","Drug Discovery","Global Health","Novel Therapeutics","Patient-First Science","Zero Point Five Therapeutics",{},"\"Developing safe and efficacious treatments for neglected diseases is not just a scientific challenge — it is a moral imperative.\"","Science in service of the *overlooked*.",[124,125],"Neglected diseases disproportionately affect billions of people in low- and middle-income communities, yet they receive a fraction of global pharmaceutical research and development investment. The gap between need and resource is one of the most pressing inequities in modern medicine.","At Zero Point Five Therapeutics, Inc., we are committed to closing that gap — and we have moved beyond early research to the frontlines of clinical validation. Our lead program is now in Phase 3 clinical trials, combining rigorous scientific methodology with a genuine moral urgency to deliver therapeutic solutions that are both safe and highly effective for populations that have been left behind.",{"label":127,"href":11},"Learn More",[129,130,131,132,133,136],{"label":42,"href":43},{"label":36,"href":45},{"label":47,"href":48},{"label":50,"href":51},{"label":134,"href":135},"About","#about",{"label":53,"href":11},"Phase 3. *The final mile.*","Clinical Pipeline","Lead program currently enrolling in Phase 3 pivotal trial across multiple international clinical sites.",[141,145,148,151,155,159],{"label":142,"sublabel":143,"status":144},"Preclinical","Target ID & Lead Opt.","done",{"label":146,"sublabel":147,"status":144},"Phase 1","Safety & PK",{"label":149,"sublabel":150,"status":144},"Phase 2","Proof of Concept",{"label":152,"sublabel":153,"status":154},"Phase 3","Pivotal Trial","active",{"label":156,"sublabel":157,"status":158},"NDA \u002F BLA","Regulatory Filing","future",{"label":160,"sublabel":161,"status":158},"Approval","Market Access","Zero Point Five Therapeutics is developing safe and efficacious therapeutic interventions for neglected tropical diseases, rare & orphan conditions, and drug-resistant infections. Lead program currently in Phase 3.","\u002Fog\u002Fdefault.jpg","ZP5 Therapeutics — Treatments for Neglected Diseases","site\u002Findex","8OfwCKyQgTg28kv-Q_sWpvKqaqTTJpvjGzEKQxRJKUY",{"id":168,"title":86,"body":169,"description":237,"extension":248,"lastUpdated":249,"meta":250,"navigation":251,"path":87,"seo":252,"stem":253,"__hash__":254},"legal\u002Flegal\u002Fterms.md",{"type":170,"value":171,"toc":236},"minimark",[172,183,188,191,195,198,202,205,209,212,216,219,223,226,229],[173,174,175],"blockquote",{},[176,177,178,182],"p",{},[179,180,181],"strong",{},"Placeholder"," — this page contains template language and has not been reviewed by counsel. Replace before launch.",[184,185,187],"h2",{"id":186},"acceptance","Acceptance",[176,189,190],{},"By accessing zeropointfivetherapeutics.com, you agree to be bound by these terms. If\nyou do not agree, please do not use the site.",[184,192,194],{"id":193},"informational-use-only","Informational use only",[176,196,197],{},"The content on this site is provided for general informational purposes only. It is\nnot intended as medical advice, an offer to sell or solicitation to buy securities,\nor a recommendation regarding any specific therapeutic course of action. Always seek\nthe advice of a qualified healthcare professional with any medical questions.",[184,199,201],{"id":200},"forward-looking-statements","Forward-looking statements",[176,203,204],{},"This site contains forward-looking statements regarding clinical development,\nregulatory strategy, and potential commercialization of ZP5 product candidates. These\nstatements involve risks and uncertainties that could cause actual results to differ\nmaterially from those projected.",[184,206,208],{"id":207},"intellectual-property","Intellectual property",[176,210,211],{},"All content on this site, including text, graphics, logos, and design, is the\nproperty of Zero Point Five Therapeutics, Inc. or its licensors and is protected by\napplicable intellectual property laws. You may not reproduce or distribute material\nfrom this site without permission.",[184,213,215],{"id":214},"no-warranty","No warranty",[176,217,218],{},"The site is provided \"as is\" without warranties of any kind, express or implied.",[184,220,222],{"id":221},"governing-law","Governing law",[176,224,225],{},"These terms are governed by the laws of the United States and the State of Maryland,\nwithout regard to conflict-of-laws principles.",[184,227,53],{"id":228},"contact",[176,230,231,232,235],{},"Questions about these terms can be sent to\n",[233,234,65],"a",{"href":66},".",{"title":237,"searchDepth":238,"depth":239,"links":240},"",2,3,[241,242,243,244,245,246,247],{"id":186,"depth":238,"text":187},{"id":193,"depth":238,"text":194},{"id":200,"depth":238,"text":201},{"id":207,"depth":238,"text":208},{"id":214,"depth":238,"text":215},{"id":221,"depth":238,"text":222},{"id":228,"depth":238,"text":53},"md","2026-04-21",{},true,{"title":86,"description":237},"legal\u002Fterms","cqNH1X5nq9f4K1Tep2RrXuDQU-AIlBYx8it_Wxpl5Ok",1777662005158]